FDAnews Drug Daily Bulletin

Pfizer's Lipitor Down, Chantix Up in 2007

Jan. 31, 2008

Pharmaceutical revenue from Pfizer’s U.S. operations decreased last year as competition in the cholesterol market contributed to an 8 percent decline in revenues for the firm’s flagship product Lipitor. The company’s $48.6 billion 2007 total revenue was 1 percent better than its 2006 revenue of $48.4 billion.

Overall, the company’s domestic revenue dropped 11 percent to $21.74 billion in 2007. Lipitor (atorvastatin calcium) had revenue of approximately $7.2 billion in the U.S. last year compared with approximately $7.85 billion in 2006. Worldwide Lipitor revenues were approximately $12.7 billion, a 2 percent decrease from 2006.

Products in other markets fared much better. Smoking cessation drug Chantix (varenicline), which has been used by more than 5 million people worldwide, neared blockbuster status in 2007 with worldwide revenue of approximately $883 million.

The firm also posted strong results for antiseizure medication Lyrica (pregabalin). The drug brought in $320 million during the fourth quarter of 2007 in the U.S., a 15 percent sequential increase from the third quarter.